Global Health

MEDANTA closed at ₹1390.0 on 2026-11-06, marking a flat day (+0.0%) after a significant +5.7% surge on 2026-11-04 accompanied by extreme volume (11.16x ratio). The daily trend is established and bullish, with the price trading above all key moving averages and the Supertrend. However, this short-term strength contrasts with a bearish monthly Supertrend and weak monthly momentum (ADX 10.7), suggesting the recent rally may be a counter-trend move within a longer-term consolidation or downtrend. The stock is positioned in the upper-middle of its 252-day range (+73.8%) and near the top of its 20-day range (+78.5%). Immediate resistance lies at ₹1407.3 (pivot, +1.24%), while support is found at ₹1365.3 (-1.78%). Anomalies indicate high participation without clear directional follow-through on the weekly timeframe, signaling potential indecision.

Global Health Limited (MEDANTA) submitted its unaudited financial results for the second quarter and half-year ended September 30, 2026, to the NSE and BSE on November 3, 2026. The Board approved these results, which were subject to a limited review by statutory auditors Walker Chandiok & Co LLP. For Q2 FY2027, revenue from operations rose 33.6% year-over-year to ₹14,690 million, while operating EBITDA increased 60.2% to ₹3,701 million with margins expanding to 25.2%. Profit after PAT grew 38.3% to ₹2,191 million. Operational metrics showed inpatient volumes up 29.5% and outpatient footfalls up 37.9%, supporting total census bed capacity of 3,115 at 67% occupancy.

On the capital allocation front, the Board approved a project budget of ₹997 Crores for constructing a 500-bedded hospital in Ghaziabad, Uttar Pradesh. This includes land costs of ₹165.82 Crores for a 10,560.36 sq. meter parcel allotted via e-auction. The company also disclosed a broader planned capital expenditure of approximately ₹62,390 million over the next 4-5 years to support expansion in Mumbai, Delhi, Guwahati, Varanasi, and Ghaziabad. Funding is expected through internal accruals and debt.

MEDANTA Global Health demonstrates a robust operational trajectory in Q2 FY2026-27, with revenue from operations surging 34% year-on-year to ₹1,469 crore. This growth is accompanied by significant earnings expansion: net profit rose to ₹219 crore and basic EPS increased to ₹8.21 per share, up from ₹5.91 in the prior quarter. Operating profit jumped to ₹370 crore, reflecting strong top-line momentum.

Financial health remains solid despite aggressive expansion. The company’s cash conversion cycle improved to -26 days as of Mar 2026, indicating efficient working capital management. However, balance-sheet leverage has risen; borrowings increased to ₹1,353 crore as of Sep 2026, and finance costs for the quarter reached ₹28.1 crore. Cash reserves declined sharply from ₹759 crore to ₹296 crore over the year, while fixed assets grew to ₹3,957 crore, signaling heavy investment in capacity. Return on Capital Employed (ROCE) moderated to 17% from 20% in Mar 2025, suggesting the new assets are still ramping up efficiency.

Ownership patterns show increasing institutional interest, with Domestic Institutional Investors (DIIs) raising their stake to 17.01%, while Foreign Institutional Investors (FIIs) reduced theirs to 9.92%. Promoter holding remained stable at 33.0%.

MEDANTA (Global Health) faces near-term technical headwinds as the stock trades in a bearish monthly and weekly trend, with the Supertrend indicator signaling downside pressure on both timeframes. The share price has retreated from recent highs, currently sitting at ₹1390.0, below the immediate pivot resistance of ₹1407.3 and the recent high of ₹1421.08. This consolidation follows a +6% post-earnings surge, suggesting the market is digesting prior gains rather than extending them immediately. Volatility remains elevated, with an annualized volatility of +31.8% and an Average True Range (ATR) of 3.66%, indicating significant price fluctuation risk. Additionally, the stock is experiencing a current drawdown of -7.9% against its peak, while the 50-day moving average slope has turned negative (-4.78), contrasting with the positive momentum seen over the past month (+6.9%).